Overview

Pharmacokinetics and Safety of ALA in Acne Vulgaris

Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics and safety of ALA in patients with moderate and severe acne vulgaris after single dose in different dosages.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Treatments:
Aminolevulinic Acid